"Gavi's Innovative Six-in-One Vaccine Scheme Accelerates Global Outbreak Response"

The Board of Gavi, the Vaccine Alliance, has approved investments in a six-in-one vaccine and discussed potential new vaccines for lower-income countries. Gavi will continue to provide COVID-19 vaccines to high-risk groups until 2025 and has approved pilot investments for investigational candidate vaccines against Marburg and Ebola Sudan. The Board also emphasized Gavi's role in pandemic prevention and response, including supporting vaccine manufacturing in Africa. Gavi aims to expand access to new vaccines and strengthen global health security by establishing pilot stockpiles of investigational vaccines for outbreak response. The Board also discussed plans for future vaccine investment strategies and acknowledged the importance of vaccines in addressing climate change and epidemic threats.